Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα -mediated inhibition of Glioma cell motility in vitro

Authors: Justyna Drukala, Katarzyna Urbanska, Anna Wilk, Maja Grabacka, Ewa Wybieralska, Luis Del Valle, Zbigniew Madeja, Krzysztof Reiss

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

Glioblastomas are characterized by rapid cell growth, aggressive CNS infiltration, and are resistant to all known anticancer regimens. Recent studies indicate that fibrates and statins possess anticancer potential. Fenofibrate is a potent agonist of peroxisome proliferator activated receptor alpha (PPARα) that can switch energy metabolism from glycolysis to fatty acid β-oxidation, and has low systemic toxicity. Fenofibrate also attenuates IGF-I-mediated cellular responses, which could be relevant in the process of glioblastoma cell dispersal.

Methods

The effects of fenofibrate on Glioma cell motility, IGF-I receptor (IGF-IR) signaling, PPARα activity, reactive oxygen species (ROS) metabolism, mitochondrial potential, and ATP production were analyzed in human glioma cell lines.

Results

Fenofibrate treatment attenuated IGF-I signaling responses and repressed cell motility of LN-229 and T98G Glioma cell lines. In the absence of fenofibrate, specific inhibition of the IGF-IR had only modest effects on Glioma cell motility. Further experiments revealed that PPARα-dependent accumulation of ROS is a strong contributing factor in Glioma cell lines responses to fenofibrate. The ROS scavenger, N-acetyl-cysteine (NAC), restored cell motility, improved mitochondrial potential, and increased ATP levels in fenofibrate treated Glioma cell lines.

Conclusions

Our results indicate that although fenofibrate-mediated inhibition of the IGF-IR may not be sufficient in counteracting Glioma cell dispersal, PPARα-dependent metabolic switch and the resulting ROS accumulation strongly contribute to the inhibition of these devastating brain tumor cells.
Appendix
Available only for authorised users
Literature
1.
Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME: Molecular targets of glioma invasion. Cell Mol Life Sci. 2007, 64: 458-478.CrossRefPubMed
2.
Terzis AJ, Niclou SP, Rajcevic U, Danzeisen C, Bjerkvig R: Cell therapies for glioblastoma. Expert Opin Biol Ther. 2006, 6: 739-749.CrossRefPubMed
3.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352: 997-1003.CrossRefPubMed
4.
Stupp R, Weber DC: The role of radio- and chemotherapy in glioblastoma. Onkologie. 2005, 28: 315-317.CrossRefPubMed
5.
Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006, 12: 4899-4907.CrossRefPubMed
6.
Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD: Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience. 2007, 145: 795-811.CrossRefPubMed
7.
Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J: Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides. 2007, 17: 201-212.CrossRefPubMed
8.
Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999, 9: 469-479.CrossRefPubMed
9.
10.
Resnicoff M, Tjuvajev J, Rotman HL, Abraham D, Curtis M, Aiken R, Baserga R: Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J Exp Ther Oncol. 1996, 1: 385-389.PubMed
11.
D'Ambrosio C, Ferber A, Resnicoff M, Baserga R: A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 1996, 56: 4013-4020.PubMed
12.
Urbanska K, Pannizzo P, Grabacka M, Croul S, Del Valle L, Khalili K, Reiss K: Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int J Cancer. 2008, 123: 1015-1024.PubMedCentralCrossRefPubMed
13.
Grabacka M, Placha W, Plonka PM, Pajak S, Urbanska K, Laidler P, Slominski A: Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res. 2004, 296: 54-58.CrossRefPubMed
14.
Grabacka M, Plonka PM, Urbanska K, Reiss K: Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res. 2006, 12: 3028-3036.CrossRefPubMed
15.
Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, Laforme AM, Chaponis DM, Folkman J, Kieran MW: PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA. 2008, 105: 985-990.PubMedCentralCrossRefPubMed
16.
17.
Holland CM, Saidi SA, Evans AL, Sharkey AM, Latimer JA, Crawford RA, Charnock-Jones DS, Print CG, Smith SK: Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets. Mol Cancer Ther. 2004, 3: 993-1001.PubMed
18.
Saidi SA, Holland CM, Charnock-Jones DS, Smith SK: In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006, 5: 13-PubMedCentralCrossRefPubMed
19.
Thuillier P, Anchiraico GJ, Nickel KP, Maldve RE, Gimenez-Conti I, Muga SJ, Liu KL, Fischer SM, Belury MA: Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion. Mol Carcinog. 2000, 29: 134-142.CrossRefPubMed
20.
Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990, 347: 645-650.CrossRefPubMed
21.
Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J: PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?. J Intern Med. 2007, 262: 184-198.CrossRefPubMed
22.
Staels B, Van Tol A, Fruchart JC, Auwerx J: Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Isr J Med Sci. 1996, 32: 490-498.PubMed
23.
Steiner G: Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Am J Cardiol. 2008, 102: 28L-33L.CrossRefPubMed
24.
Jiao HL, Ye P, Zhao BL: Protective effects of green tea polyphenols on human HepG2 cells against oxidative damage of fenofibrate. Free Radic Biol Med. 2003, 35: 1121-1128.CrossRefPubMed
25.
Nishimura J, Dewa Y, Muguruma M, Kuroiwa Y, Yasuno H, Shima T, Jin M, Takahashi M, Umemura T, Mitsumori K: Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. Toxicol Sci. 2007, 97: 44-54.CrossRefPubMed
26.
Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004, 4: 505-518.CrossRefPubMed
27.
Reiss K, Valentinis B, Tu X, Xu SQ, Baserga R: Molecular markers of IGF-I-mediated mitogenesis. Exp Cell Res. 1998, 242: 361-372.CrossRefPubMed
28.
Korohoda W, Golda J, Sroka J, Wojnarowicz A, Jochym P, Madeja Z: Chemotaxis of Amoeba proteus in the developing pH gradient within a pocket-like chamber studied with the computer assisted method. Cell Motil Cytoskeleton. 1997, 38: 38-53.CrossRefPubMed
29.
Czyz J, Madeja Z, Irmer U, Korohoda W, Hulser DF: Flavonoid apigenin inhibits motility and invasiveness of carcinoma cells in vitro. Int J Cancer. 2005, 114: 12-18.CrossRefPubMed
30.
Sroka J, Antosik A, Czyz J, Nalvarte I, Olsson JM, Spyrou G, Madeja Z: Overexpression of thioredoxin reductase 1 inhibits migration of HEK-293 cells. Biol Cell. 2007, 99: 677-687.CrossRefPubMed
31.
Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995, 96: 741-750.PubMedCentralCrossRefPubMed
32.
Yang S, Chintapalli J, Sodagum L, Baskin S, Malhotra A, Reiss K, Meggs LG: Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am J Physiol Renal Physiol. 2005, 289: F1144-1152.CrossRefPubMed
33.
Cossarizza A, Salvioli S: Flow cytometric analysis of mitochondrial membrane potential using JC-1. Curr Protoc Cytom. 2001, Chapter 9:Unit 9 14
34.
Goto M, Holgersson J, Kumagai-Braesch M, Korsgren O: The ADP/ATP ratio: A novel predictive assay for quality assessment of isolated pancreatic islets. Am J Transplant. 2006, 6: 2483-2487.CrossRefPubMed
35.
Guvakova MA: Insulin-like growth factors control cell migration in health and disease. Int J Biochem Cell Biol. 2007, 39: 890-909.CrossRefPubMed
36.
Urbanska K, Trojanek J, Del Valle L, Eldeen MB, Hofmann F, Garcia-Echeverria C, Khalili K, Reiss K: Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene. 2007, 26: 2308-2317.CrossRefPubMed
37.
Scatena R, Bottoni P, Giardina B: Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?. PPAR Res. 2008, 2008: 256251-PubMedCentralCrossRefPubMed
38.
Warburg O: On respiratory impairment in cancer cells. Science. 1956, 124: 269-270.PubMed
39.
Li N, Brun T, Cnop M, Cunha DA, Eizirik DL, Maechler P: Transient oxidative stress damages mitochondrial machinery inducing persistent beta-cell dysfunction. J Biol Chem. 2009, 28 (284(35)): 23602-12. 10.1074/jbc.M109.024323.CrossRef
40.
Monsalve M, Borniquel S, Valle I, Lamas S: Mitochondrial dysfunction in human pathologies. Front Biosci. 2007, 12: 1131-1153.CrossRefPubMed
41.
Husain M, Meggs LG, Vashistha H, Simoes S, Griffiths KO, Kumar D, Mikulak J, Mathieson PW, Saleem MA, Del Valle L: Inhibition of p66ShcA longevity gene rescues podocytes from HIV-1-induced oxidative stress and apoptosis. J Biol Chem. 2009, 284: 16648-16658.PubMedCentralCrossRefPubMed
42.
Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R: In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 2004, 5: 231-239.CrossRefPubMed
43.
Hewish M, Chau I, Cunningham D: Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009, 4: 54-72.CrossRefPubMed
44.
Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, Baserga R, Iliakis G, Aiken RD: Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol. 2001, 19: 2189-2200.PubMed
45.
Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S: Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 2008, 177: 137-150.CrossRefPubMed
46.
Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B: The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1997, 1332: F105-126.PubMed
47.
Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R: The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995, 55: 2463-2469.PubMed
48.
Valentinis B, Morrione A, Peruzzi F, Prisco M, Reiss K, Baserga R: Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion. Oncogene. 1999, 18: 1827-1836.CrossRefPubMed
49.
Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, Croul S, Peruzzi F, Khalili K, Reiss K: Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene. 2001, 20: 3857-3868.CrossRefPubMed
50.
Valentinis B, Reiss K, Baserga R: Insulin-like growth factor-I-mediated survival from anoikis: role of cell aggregation and focal adhesion kinase. J Cell Physiol. 1998, 176: 648-657.CrossRefPubMed
51.
Perer ES, Madan AK, Shurin A, Zakris E, Romeguera K, Pang Y, Beech DJ: Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells. J Surg Res. 2000, 94: 1-5.CrossRefPubMed
52.
Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997, 57: 3079-3083.PubMed
53.
Zandi E, Chen Y, Karin M: Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science. 1998, 281: 1360-1363.CrossRefPubMed
54.
Gamerdinger M, Clement AB, Behl C: Cholesterol-like effects of selective COX inhibitors and fibrates on cellular membranes and amyloid-{beta} production. Mol Pharmacol. 2007
55.
56.
Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y: Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006, 10: 51-64.PubMedCentralCrossRefPubMed
57.
58.
Matoba S, Kang JG, Patino W, Wragg A, Boehm M, Gavrilova O, Hurley P, Bunz F, Hwang PM: p53 regulates mitochondrial respiration. Science. 2006, 312: 1650-1653.CrossRefPubMed
59.
Finck BN, Kelly DP: Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol. 2002, 34: 1249-1257.CrossRefPubMed
60.
Randle PJ: Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev. 1998, 14: 263-283.CrossRefPubMed
61.
Wolfe RR: Metabolic interactions between glucose and fatty acids in humans. Am J Clin Nutr. 1998, 67: 519S-526S.PubMed
62.
Beckner ME, Gobbel GT, Abounader R, Burovic F, Agostino NR, Laterra J, Pollack IF: Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest. 2005, 85: 1457-1470.CrossRefPubMed
63.
Scatena R, Bottoni P, Vincenzoni F, Messana I, Martorana GE, Nocca G, De Sole P, Maggiano N, Castagnola M, Giardina B: Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator. Chem Res Toxicol. 2003, 16: 1440-1447.CrossRefPubMed
64.
Jiao HL, Zhao BL: Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol Appl Pharmacol. 2002, 185: 172-179.CrossRefPubMed
65.
Raha S, Myint AT, Johnstone L, Robinson BH: Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase. Free Radic Biol Med. 2002, 32: 421-430.CrossRefPubMed
66.
Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, Ezaki O: Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes. J Biol Chem. 2002, 277: 9562-9569.CrossRefPubMed
67.
Pecqueur C, Bui T, Gelly C, Hauchard J, Barbot C, Bouillaud F, Ricquier D, Miroux B, Thompson CB: Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysis-derived pyruvate utilization. Faseb J. 2008, 22: 9-18.CrossRefPubMed
68.
Friedl P, Noble PB, Zanker KS: Lymphocyte locomotion in three-dimensional collagen gels. Comparison of three quantitative methods for analysing cell trajectories. J Immunol Methods. 1993, 165: 157-165.CrossRefPubMed
Metadata
Title
ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα -mediated inhibition of Glioma cell motility in vitro
Authors
Justyna Drukala
Katarzyna Urbanska
Anna Wilk
Maja Grabacka
Ewa Wybieralska
Luis Del Valle
Zbigniew Madeja
Krzysztof Reiss
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-159

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Epstein-Barr virus-encoded EBNA1 enhances RNA polymerase III-dependent EBER expression through induction of EBER-associated cellular transcription factors

Research

MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1α/HIF-1β

Review

Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia

Research

Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker

Research

Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia

Review

Glycogen synthase kinase 3 beta: can it be a target for oral cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits